-
- Target Alle ITGA2 Antikörper anzeigen
- ITGA2 (Integrin alpha 2 (ITGA2))
-
Reaktivität
- Maus
-
Wirt
- Ratte
-
Klonalität
- Monoklonal
-
Konjugat
- Dieser ITGA2 Antikörper ist konjugiert mit FITC
-
Applikation
- Flow Cytometry (FACS)
- Produktmerkmale
- Purified IgM conjugated to Fluorescein Isothiocyanate Isomer 1 (FITC)
- Klon
- DX5
- Isotyp
- IgM
- Top Product
- Discover our top product ITGA2 Primärantikörper
-
-
- Applikationshinweise
- Optimal working dilution should be determined by the investigator.
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Liquid
- Konzentration
- 0.1 mg/mL
-
-
Combined immunogene therapy of IL-6 and IL-15 enhances anti-tumor activity through augmented NK cytotoxicity." in: Cancer letters, Vol. 272, Issue 2, pp. 285-95, (2008) (PubMed).
: "
-
Combined immunogene therapy of IL-6 and IL-15 enhances anti-tumor activity through augmented NK cytotoxicity." in: Cancer letters, Vol. 272, Issue 2, pp. 285-95, (2008) (PubMed).
-
- Target
- ITGA2 (Integrin alpha 2 (ITGA2))
- Andere Bezeichnung
- CD49b (ITGA2 Produkte)
- Hintergrund
- Synonyms: INTEGRIN ALPHA 2 CHAIN, VLA-2
- Gen-ID
- 16398
- UniProt
- Q62469
- Pathways
- CXCR4-mediated Signaling Events, Smooth Muscle Cell Migration, Integrin Complex
-